Last reviewed · How we verify
Trabeculectomy with MMC
Trabeculectomy with MMC is a Small molecule drug developed by Pro Top & Mediking Company Limited. It is currently FDA-approved for Open-angle glaucoma refractory to medical therapy, Angle-closure glaucoma, Secondary glaucomas.
Trabeculectomy with MMC is a surgical procedure that creates a drainage pathway in the eye while using mitomycin C to prevent scar tissue formation and maintain long-term filtration.
Trabeculectomy with MMC is a surgical procedure used to treat conditions such as glaucoma, neovascular glaucoma, and primary open angle glaucoma. Mitomycin-C, a small molecule used in this procedure, is administered as an adjunctive therapy before surgery to prevent scarring.
At a glance
| Generic name | Trabeculectomy with MMC |
|---|---|
| Sponsor | Pro Top & Mediking Company Limited |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Trabeculectomy is a glaucoma surgery that removes a portion of the trabecular meshwork to allow aqueous humor to drain from the anterior chamber into a subconjunctival bleb, thereby lowering intraocular pressure. Mitomycin C (MMC) is an antimetabolite applied intraoperatively to inhibit fibroblast proliferation and reduce postoperative scarring, which improves the long-term success rate of the filtration bleb.
Approved indications
- Open-angle glaucoma refractory to medical therapy
- Angle-closure glaucoma
- Secondary glaucomas
Common side effects
- Hypotony (low intraocular pressure)
- Bleb-related infection (blebitis/endophthalmitis)
- Cataract progression
- Corneal erosion or scarring
- Hyphema
Key clinical trials
- Preserflo MicroShunt Versus Trabeculectomy (NA)
- Quality of Life After Glaucoma Surgery: Evaluating the Patient Perspective Across Surgical Options
- Clinical Study Evaluating the Safety and Performance of the MIST Device for Intraocular Pressure Reduction in Patients With Primary Open-Angle Glaucoma (NA)
- SCTSC Versus Trabeculectomy in Medically Uncontrolled Open-Angle Glaucoma in Pseudophakic Patients (NA)
- Intracameral Versus Intravitreal Bevacizumab Injection in NVG: RCT (NA)
- Electron Microscopic Examination of Iris Tissue in Buphthalmos (NA)
- SIGHT Study: Cost-effectiveness of InnFocus Microshunt Implantation vs. Trabeculectomy. (NA)
- Analysis of Conjunctival Changes as Indicators for Ab-interno Gelatin Microstent Implantation Surgery Outcomes (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Trabeculectomy with MMC CI brief — competitive landscape report
- Trabeculectomy with MMC updates RSS · CI watch RSS
- Pro Top & Mediking Company Limited portfolio CI
Frequently asked questions about Trabeculectomy with MMC
What is Trabeculectomy with MMC?
How does Trabeculectomy with MMC work?
What is Trabeculectomy with MMC used for?
Who makes Trabeculectomy with MMC?
What development phase is Trabeculectomy with MMC in?
What are the side effects of Trabeculectomy with MMC?
Related
- Manufacturer: Pro Top & Mediking Company Limited — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Open-angle glaucoma refractory to medical therapy
- Indication: Drugs for Angle-closure glaucoma
- Indication: Drugs for Secondary glaucomas
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing